Skip to main navigationSkip to main content
The University of Southampton
Southampton Clinical Trials UnitNews

SPIRE trial publishes trial protocol in open access journal

Published: 16 April 2018
Cancer cells picture
Cancer cells studied in SPIRE trial

SPIRE is funded by CRUK as part of the ECMC combinations alliance. SPIRE will provide evidence for whether SGI-110 in combination with GC chemotherapy is safe and biologically effective prior to future phase II/III trials as a neoadjuvant therapy for UBC and potentially in other cancers treated with GC.





SPIRE– combining SGI-110 with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer: study protocol for a phase Ib/randomised IIa open label clinical trial


Simon Crabb,
Sarah J. Danson,
James W. F. Catto,
Cathy McDowell,
James N. Lowder,
Joshua Caddy,
Denise Dunkley Email author,
Jessica Rajaram,
Deborah Ellis,
Stephanie Hill,
David Hathorn,
Amy Whitehead,
Mihalis Kalevras,
Robert Huddart and
Gareth Griffiths



This trial is funded via the ECMC Combination Alliance which includes funding from Cancer Research UK (C9317/A19903) and investigator-initiated research support from Astex Pharmaceuticals for free drug (plus labelling and distribution), Clinical Trials Unit running costs and translational funding. The trial is supported by Cancer Research UK core funding at the Southampton Clinical Trials Unit and ECMC core funding at Southampton.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.